11/7/26 Leveraging Natural History and RWE for Rare Approvals Previous The Plausible Mechanism Pathway: A New Evidence Playbook for Rare Disease Development Next Accelerated Pathways and Global Harmonization You Might Also Like Myth-Busting Hybrid & Home-Based Trials: What’s Real, What’s Not and What Scales Commercial Success in Rare Disease Takes an Ecosystem: Aligning Manufacturers, Specialty Pharmacy, Providers, and Patient Support Mock Formal FDA Meeting: How to Respond When FDA Disagrees OPENING KEYNOTE - From Breakthrough to Access: How Advocacy and Policy Decide What Reaches Patients. From Parent Advocacy to IND: Building a Treatment Pathway for an Ultra-Rare Disease
11/7/26 Leveraging Natural History and RWE for Rare Approvals Previous The Plausible Mechanism Pathway: A New Evidence Playbook for Rare Disease Development Next Accelerated Pathways and Global Harmonization You Might Also Like Myth-Busting Hybrid & Home-Based Trials: What’s Real, What’s Not and What Scales Commercial Success in Rare Disease Takes an Ecosystem: Aligning Manufacturers, Specialty Pharmacy, Providers, and Patient Support Mock Formal FDA Meeting: How to Respond When FDA Disagrees OPENING KEYNOTE - From Breakthrough to Access: How Advocacy and Policy Decide What Reaches Patients. From Parent Advocacy to IND: Building a Treatment Pathway for an Ultra-Rare Disease
